GGrantIndex
← Leaderboards

John M Olichney

University Of California San Diego

$15,137,364
Attributed
$17,240,359
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.6M · FY200523
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$17,240,359 · 6

By mechanism

R01$10,697,588 · 3
P30$6,542,771 · 2
M01$0 · 1

Top collaborators

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposNeuropsychological TestsBrainElderlyEnrollmentDementiaImpaired CognitionCognitiveBiological MarkersMagnetic Resonance ImagingS DiseaseCohortPublic HealthNeuroimagingDiagnosticCommunitiesAging BrainProtocols DocumentationPositron-Emission TomographySamplingBaseCognitive ChangeNeurotoxicityBrain Region

Grant awards (33)

Clinical Core$1,117,722
P30 · FY2023 · AG · contact PI
Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia$399,007
R01 · FY2023 · AG · contact PI
Clinical Core$1,114,229
P30 · FY2022 · AG · contact PI
Clinical Core$1,096,764
P30 · FY2021 · AG · contact PI
Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia$955,397
R01 · FY2021 · AG · contact PI
Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia$931,742
R01 · FY2020 · AG · contact PI
Core B: Clinical Core$709,995
P30 · FY2020 · AG · contact PI
Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials$668,423
R01 · FY2020 · AG · contact PI
Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia$950,568
R01 · FY2019 · AG · contact PI
Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials$709,159
R01 · FY2019 · AG · contact PI
Core B: Clinical Core$626,016
P30 · FY2019 · AG · contact PI
Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia$952,695
R01 · FY2018 · AG · contact PI
Core B: Clinical Core$626,015
P30 · FY2018 · AG · contact PI
Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials$977,234
R01 · FY2017 · AG · contact PI
Phase II RCT of High-dose Vitamin D Supplements in Older Adults without Dementia$960,877
R01 · FY2017 · AG · contact PI
Core B: Clinical Core$626,015
P30 · FY2017 · AG · contact PI
Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials$957,278
R01 · FY2016 · AG · contact PI
Core B: Clinical Core$626,015
P30 · FY2016 · AG · contact PI
Longitudinal Cognitive ERP studies: Advancement for AD Clinical Trials$893,896
R01 · FY2015 · AG · contact PI
Memory in Aging, Mild Cognitive impairment and AD$268,800
R01 · FY2005 · AG
Memory in Aging, Mild Cognitive impairment and AD$268,800
R01 · FY2004 · AG
Memory in Aging, Mild Cognitive impairment and AD$268,800
R01 · FY2003 · AG
Memory in Aging, Mild Cognitive impairment and AD$268,800
R01 · FY2002 · AG
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2002 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2002 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2002 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2002 · RR
Memory in Aging, Mild Cognitive impairment and AD$266,112
R01 · FY2001 · AG
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2001 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2001 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2000 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2000 · RR
EFFECTS OF NICOTINE ON ERPS IN ALZHEIMERS DISEASE$0
M01 · FY2000 · RR